Bharat Parenterals Ltd (BPLPHARMA) — shareholding pattern, promoter holding, financials and share price

About Bharat Parenterals Ltd (BPLPHARMA)

Bharat Parenterals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BPLPHARMA and on the BSE under scrip code 541096. Its ISIN is INE365Y01019.

Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations [1]

Arisinfra Solutions Limited is an asset-light construction materials and services platform that aggregates suppliers, supplies construction materials across multiple categories, provides contract manufacturing and value-added services, and supports project lifecycle delivery through technology-enabled logistics and execution capabilities for developers and contractors.

Q3 FY26 was the company’s strongest quarter with Total Income of ₹272.5 crore, Revenue from Operations of ₹270.8 crore (49% YoY, 12% QoQ), EBITDA of ₹30 crore (106% YoY) and Reported PAT of ₹18.3 crore, reflecting improved mix, tighter working capital and disciplined cost management driving material margin expansion.

Listed peers in Pharmaceuticals: Themis Medicare Ltd, Wanbury Ltd, Kopran Ltd, Shree Ganesh Remedies Ltd, Hexagon Nutrition Ltd, Remus Pharmaceuticals Ltd.

Valuation & Returns

10 Jul 2026

At ₹1,402 a share on 10 Jul 2026, Bharat Parenterals Ltd (BPLPHARMA) was valued at a price-to-earnings ratio of 57.3x against an industry P/E of 36.41x and a price-to-book of 2.92x on a book value of ₹479.79 per share as of Mar 2025. Solomo computes return on equity of -8.26% and return on capital employed of -1.73% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
57.3x
Industry P/E
36.41x
P/B
2.92x
EPS (TTM)
₹-39.61
Book value / share
₹479.79
ROE
-8.26%
ROCE
-1.73%
ROA
-4.21%
Debt / equity
0.54x
Dividend yield
0.06%
EBITDA margin
7.34%
52-week range
₹880.25 – ₹1,667.2

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Bharat Parenterals Ltd (BPLPHARMA) reported revenue of ₹345 crore, net profit of ₹-27 crore and earnings per share of ₹-11.88. That compares with revenue of ₹340 crore and net profit of ₹-44 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹99.62 crore and net profit ₹-8.16 crore (consolidated).

Consolidated annual results for Bharat Parenterals Ltd (BPLPHARMA), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)212218261340345
Net profit (₹ cr)211611-44-27
EPS (₹)36.4528.4724.95-18.33-11.88
Compound annual growth for Bharat Parenterals Ltd (BPLPHARMA). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth10.30%6.09%8.08%30.30%
Profit growth16.97%0.12%7.48%-515.60%
Stock price CAGR-28%46%-18%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 67.2% of Bharat Parenterals Ltd (BPLPHARMA) (up 0.03 pp QoQ), foreign institutional investors (FII) hold 0.11% and domestic institutional investors (DII) hold 1.37%. Market capitalisation was ₹966 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2018.

Largest disclosed public shareholders in Jun 2026: ASOJ SOFT CAPS PVTLTD(ANCHOR) 4.94%, ASHISH KACHOLIA 1.87%, MADHULIKA AGARWAL 1.87%, SOHINI GIRISH PATEL 1.41%, MANOHAR DEVABHAKTUNI 1.37%, RAJASTHAN GLOBAL SECURITIES PRIVATE LIMI 1.08%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202667.2%-0.11%1.37%32.8%
Mar 202667.17%-0.11%1.06%32.83%
Dec 202567.19%-0.11%0.54%32.81%
Sep 202567.19%-0.11%0.54%32.81%
Jun 202567.19%-0.11%0.54%32.81%
Mar 202567.2%-0.11%0.54%32.8%
Dec 202467.2%-0.11%0.54%32.8%
Sep 202465.35%-0.08%0.57%34.65%
Every quarter since Mar 2018 Filing data, not investment advice.